View DividendPrestige Biologics マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況Prestige Biologics Co., Ltd., Annual General Meeting, Sep 27, 2024Sep 13すべての更新を表示Recent updatesNew major risk - Financial position Nov 22New minor risk - Shareholder dilution Oct 25Prestige Biologics Co., Ltd. announced that it has received KRW 89.9263492 billion in fundingSep 25Prestige Biologics Co., Ltd., Annual General Meeting, Sep 27, 2024Sep 13New major risk - Financial data availability Aug 29New minor risk - Share price stability Aug 19New minor risk - Financial data availability Mar 16New major risk - Financial position Sep 19Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma LimitedSep 07CEO（最高経営責任者Prestige Biologics CEOがいない、あるいは彼らに関するデータがない。View Ownership
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma LimitedSep 07